Clinical trials: Focal Onset Seizure, open to volunteers
Seizures, Seizures, Focal
Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
The purpose of this research is to determine the optimal dose, safety and tolerability of zonisamide oral suspension in children ages 1 month to 17 years of age who have partial-onset (focal) seizures.
- Conditions
- Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial
- Trial name
- NCT06534502
- Testing
- Zonisamide Oral Product
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Azurity Pharmaceuticals
Focal Onset Seizures
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
- Trial name
- NCT06798896
- Testing
- SPN-817
- Where
- 63 sites in United States, Australia and 3 more
- Volunteers
- 216 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Focal-Onset Seizures
Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice.
- Trial name
- ENGAGE (NCT07793396)
- Testing
- Eslicarbazepine acetate
- Where
- Pakistan
- Volunteers
- 1,500 people
- Sponsor
- King Edward Medical University
Focal Seizures
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older.
- Trial name
- NCT07233239
- Testing
- CBD-OS
- Where
- 24 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Epilepsy, Encephalitis Autoimmune
Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of…
- Trial name
- NCT06388161
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shen Chun-Hong
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 2 (NCT07594119)
- Testing
- RAP-219
- Where
- 14 sites in United States, Australia
- Volunteers
- 312 people
- Sponsor
- Rapport Therapeutics Inc.
Focal Epilepsy, Generalized Seizure
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Trial name
- FORESITE (NCT07012148)
- Testing
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Epilepsy, Seizure Disorder
Epilepsy Learning Healthcare System (ELHS)
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy.
- Conditions
- Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
- Trial name
- ELHS (NCT06265103)
- Testing
- Clinical care and quality improvement
- Where
- 13 sites in United States
- Volunteers
- 100,000 people
- Sponsor
- Epilepsy Foundation of America
Epilepsy, Tonic-Clonic, Focal Seizure
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy
- Conditions
- Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
- Trial name
- NCT07287163
- Testing
- vormatrogine
- Where
- 36 sites in United States, Brazil and 4 more
- Volunteers
- 700 people
- Sponsor
- Praxis Precision Medicines
Focal Onset Seizures
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
- Trial name
- NCT07141329
- Testing
- SPN-817
- Where
- 8 sites in United States, Australia
- Volunteers
- 100 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Newly Diagnosed Epilepsy With Focus on Seizure Frequency at Onset and Long-term Seizure Control
Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, and achieving long-term seizure control remains a major therapeutic goal.
- Trial name
- NCT07343609
- Testing
- observational study (no intervention)
- Volunteers
- 100 people
- Sponsor
- Assiut University
Focal Epilepsy, Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in…
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
- Trial name
- NCT07219407
- Testing
- RAP-219
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Focal Onset Seizure
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults
This Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of AVAT-121 in healthy adults. The study includes three parts: Part A: single ascending dose.
- Trial name
- NCT07918469
- Testing
- AVAT-121, AVAT-121 and Epidyolex®
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Avata Biosciences Holdings Ltd
Focal Epilepsy With and Without Secondary Generalization
Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain
Aim of the study is to better characterize the clinical profile of adjunctive cenobamate by collecting data from the current standard clinical practice in France, Germany, and Spain, to describe the real-world clinical response…
- Trial name
- NCT06716801
- Testing
- Cenobamate
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Temporal Lobe Epilepsy, Frontal Lobe Epilepsy
Changes in Attentional Control After a Focal Seizure.
Epilepsy is frequently associated with cognitive and attentional disorders. Several studies have pointed out that there are modifications of brain activity in resting state during peri-ictal period in EEG and functional MRI.
- Conditions
- Temporal Lobe Epilepsy, Frontal Lobe Epilepsy, Others Subtypes
- Trial name
- ATTENTIONEPIF (NCT06466681)
- Testing
- All included subjects
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Focal Onset Seizures
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
The X-TOLE3 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive therapy in focal-onset seizures.
- Trial name
- NCT05716100
- Testing
- XEN1101
- Where
- 103 sites in United States, Argentina and 19 more
- Volunteers
- 360 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 1 (NCT07563881)
- Testing
- RAP-219
- Where
- 24 sites in United States, Australia and 2 more
- Volunteers
- 333 people
- Sponsor
- Rapport Therapeutics Inc.
Focal Onset Seizure, Primary Generalized Epilepsy
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
- Trial name
- NCT06908356
- Testing
- 30mg PRAX-628
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 50 people
- Sponsor
- Praxis Precision Medicines
Focal Epilepsy
Long-term Safety and Tolerability of BHV-7000
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
- Trial name
- NCT06443463
- Testing
- BHV-7000
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 660 people
- Sponsor
- Biohaven Therapeutics Ltd.
Epilepsy With Uncontrolled Focal-onset Seizures
REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures.
- Trial name
- NCT06922175
- Where
- 10 sites in Germany, Netherlands and 3 more
- Volunteers
- 200 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A